An object of the present invention is to provide a fragment antibody which can be conveniently produced as one having antigen-binding activity, and which has a greater ability to crystallize itself alone or as a complex with an antigen molecule than that of Fv-clasp (v1) even in a case where the fragment antibody is obtained in an E. coli expression system. The present invention relates to a fragment antibody including a complex of a peptide (VH(112C)-SARAH) in which an N-terminus of a SARAH domain is linked to a C-terminus of a heavy chain domain (VH region) of an antibody, and an amino acid residue of antibody residue 112 according to Chothia numbering scheme in the VH region is mutated to cysteine; and a peptide (VL-SARAH(37C)) in which an N-terminus of a SARAH domain is linked to a C-terminus of a light chain domain (VL region) of an antibody, and an amino acid residue at position 13 from the C-terminus in the SARAH domain is mutated to cysteine.

An optimized method for synthesizing dalbavancin is provided in which an organic antisolvent such as tert-butyl methyl ether (TBME) or dimethoxyethane (DME) is used to precipitate the product of the esterification of A-40926.

The present disclosure relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present disclosure relates to cyclic peptide compositions and methods for treating rheumatoid arthritis.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

An undifferentiated stem cell removal agent is provided, containing at least one component selected from the group consisting of the following (a) to (d): (a) a cell that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (b) a compound that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (c) a cell that is capable of inducing a specific immune response against a glypican-3-expressing cell; and (d) a compound that is capable of inducing a specific immune response against a glypican-3-expressing cell.

The present invention relates to modified peptides, and their use for treating a lupus-related auto-immune or inflammatory disorder, e.g., systemic lupus erythematosus (SLE or lupus).

The present invention relates to modified peptides, and their use for treating a lupus-related auto-immune or inflammatory disorder, e.g., systemic lupus erythematosus (SLE or lupus).

Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.

Cyclic compounds that selectively inhibit KRAS were found. Moreover, cyclic compounds were found to interact with an amino acid residue specific to KRAS.

The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.